Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Deficiency of factor-inhibiting HIF creates a tumor-promoting immune microenvironment.

Journal article

Ma J. et al, (2024), Proc Natl Acad Sci U S A, 121

Revaccination with BCG: does it work?

Journal article

McShane H., (2024), Lancet Infect Dis

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Journal article

Wajja A. et al, (2024), Lancet Infect Dis

Exploring the ethics of tuberculosis human challenge models.

Journal article

Rohrig A. et al, (2023), J Med Ethics

Improving TB vaccine trial efficiency: A tough nut to crack.

Journal article

Mcshane H., (2023), J Infect Dis

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge.

Journal article

Stylianou E. et al, (2023), Front Immunol, 14

BCG: Past, Present and Future Direction

Chapter

Morrison H. and McShane H., (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 171 - 195

Healthy volunteer symptom profile following research bronchoscopy

Conference paper

Morrison H. et al, (2023), EUROPEAN RESPIRATORY JOURNAL, 62

The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy

Chapter

Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25

Load More